Welcome to our dedicated page for Alzamend Neuro SEC filings (Ticker: ALZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alzamend Neuro Inc (ALZN) files regular reports with the Securities and Exchange Commission, providing transparency into its clinical development programs, financial position, and corporate governance. For clinical-stage biopharmaceutical companies, SEC filings reveal critical information about drug candidate progress, trial timelines, cash runway, and strategic partnerships that traditional financial metrics alone cannot capture.
The company's 10-K annual reports detail the scientific rationale behind AL001 and ALZN002, including preclinical data, clinical trial designs, regulatory strategies, and competitive landscape analysis. These filings explain the therapeutic mechanisms of the company's ionic cocrystal lithium delivery technology and cell-based vaccine approach, along with intellectual property protections and licensing agreements. 10-Q quarterly reports provide updates on clinical trial enrollment rates, milestone achievements, and research expenditure allocation across different programs.
Form 8-K filings announce material events such as clinical trial initiations, patient dosing milestones, partnership agreements with research institutions, and financing transactions that fund ongoing development activities. For biotech investors, these real-time disclosures often contain the most actionable information about development progress between quarterly reporting periods. Form 4 insider transaction reports reveal when executives and directors buy or sell shares, potentially signaling confidence levels in upcoming clinical readouts or regulatory interactions.
Our AI-powered summaries translate complex scientific and regulatory language into accessible explanations, highlighting key trial endpoints, cash burn rates, and development risks disclosed in these documents. Access comprehensive SEC filing coverage for Alzamend Neuro to understand the company's path through clinical development stages and toward potential regulatory approval.
Milton C. Ault III, a director and 10% owner of Alzamend Neuro (ALZN), reported multiple transactions on Form 4. On 07/23/25, his affiliate Ault Lending, LLC converted 332.7553 Series B preferred shares into 143,429 common shares at an effective price of $2.32. The same day it sold 59,516 shares at an average $2.9502; a further 9,621 shares were sold on 07/24/25 at $2.9349.
Following the transactions, Ault Lending holds 82,552 common shares. Including other entities controlled by Mr. Ault (direct 1,843; Ault Life Sciences Inc. 11,068; Ault Life Sciences Fund LLC 61), his aggregate beneficial ownership is ≈95,524 common shares. Derivative positions remain significant: 1,767.2447 Series B preferred shares (no expiration) and 45,569 warrants with strike prices ranging from $108 to $4,050 expiring 2025-2029.
The filing shows a net reduction of roughly 69,137 shares (-42% of the 07/23 conversion) in Ault Lending’s indirect stake. While the conversion eliminates some preferred stock—simplifying the capital structure—the concurrent sales by a large insider can be viewed as a bearish signal for near-term sentiment.
Alzamend Neuro, Inc. (ALZN) has filed an amended Form 144 (Form 144/A) disclosing the intent of an undisclosed shareholder to sell 939,281 shares of common stock through broker E*TRADE Financial on or about 14 July 2025 on the NASDAQ exchange. The filing lists an aggregate market value of US $3,005,699.20 for the proposed sale. For context, the company reports 2,896,432 shares outstanding, meaning the planned disposition represents roughly one-third of the free-trading equity base, a size that can materially influence trading liquidity and share-price dynamics.
The notice also details the historical acquisition of the securities: purchases span private placements, IPO participation, open-market buys, warrant exercises and a sizable 905,172-share commitment tied to Series B convertible preferred stock, plus 25,804 shares available via warrants. Although these convertible and warrant positions are not part of the current sale, their disclosure signals additional potential share supply.
Within the past three months the same party (identified in the filing as Ault Lending, LLC) sold 1,213 shares for gross proceeds of $6,138. No material adverse information is represented, and the seller certifies compliance with Rule 144.
Key takeaways for investors: (1) the block size is large relative to the float, introducing a possible overhang; (2) the transaction is a secondary sale—no new capital accrues to the company; (3) additional convertible and warrant holdings could expand the float further if exercised or converted. The filing is procedural, but the magnitude of the proposed sale makes it noteworthy for liquidity and near-term price action.
FAQ
What is the current stock price of Alzamend Neuro (ALZN)?
What is the market cap of Alzamend Neuro (ALZN)?
